MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.850 +0.540 (+7.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,331,733
Open 7.890
Bid (Size) 7.970 (100)
Ask (Size) 8.040 (100)
Prev. Close 7.310
Today's Range 7.550 - 8.220
52wk Range 3.140 - 10.08
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
One of the company's key drugs won't be challenged by a competing medication anytime soon. 
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill

Performance

YTD
N/A
N/A
1 Month
+12.8%
+12.8%
3 Month
-2.0%
-2.0%
6 Month
+66.0%
+66.0%
1 Year
+131.6%
+131.6%

More News

Read More
News headline image
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
Via Benzinga
News headline image
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
Via Chartmill
News headline image
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris (XERS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
Via Chartmill
News headline image
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗
Via Chartmill
News headline image
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 7.850
When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 12/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story